Page last updated: 2024-11-07

n-hydroxythalidomide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-hydroxythalidomide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID124398
CHEMBL ID365514
SCHEMBL ID13364982
MeSH IDM0168209

Synonyms (16)

Synonym
nsc-528759
nsc528759
n-hydroxythalidomide
2-(1-hydroxy-2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
CHEMBL365514
unii-s99d86td4b
1h-isoindole-1,3(2h)-dione, 2-(1-hydroxy-2,6-dioxo-3-piperidinyl)-
s99d86td4b ,
126663-38-5
SCHEMBL13364982
1'-hydroxy thalidomide
1'-hydroxythalidomide
1'-hydroxy thalidomide, (+/-)-
DTXSID60925664
2-(1-hydroxy-2,6-dioxopiperidin-3-yl)-1h-isoindole-1,3(2h)-dione
Q27289078

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" The purpose of this work was to evaluate the in vitro and in vivo immunosuppressive effects of Thd and its derivative, N-Hydroxythalidomide (H-Thd), alone and in combination with cyclosporin A (CsA), upon different in vitro lymphocyte activation pathways and in vivo local graft-versus-host-reaction (GvHR)."( In vitro and in vivo immunosuppressive potential of thalidomide and its derivative, N-hydroxythalidomide, alone and in combination with cyclosporin A.
Chuong, PH; Claude, JR; Galons, H; Huynh-Thien, D; Righenzi, S; Voisin, J; Warnet, JM; Zhu, J, 1997
)
0.73
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID252970Percent cell proliferation of human leukemia cell line HL-60 at 1*E-5 M2005Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
Cell differentiation inducers derived from thalidomide.
AID252627NBT positivity against human leukemia cell line HL-60 at 1*E-5 M2005Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
Cell differentiation inducers derived from thalidomide.
AID340116Antagonist activity at progesterone receptor in human T47D cells assessed as inhibition of progesterone-induced alkaline phosphatase activity at 100 uM2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Progesterone receptor antagonists with a 3-phenylquinazoline-2,4-dione/2-phenylisoquinoline-1,3-dione skeleton.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (12.50)18.7374
1990's2 (25.00)18.2507
2000's3 (37.50)29.6817
2010's1 (12.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]